Real life adjuvant chemotherapy uptake and survival in patients with non-small cell lung cancer after complete resection
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- Keywords
- Non-small cell lung cancer, adjuvant chemotherapy uptake, real-world study, survival,
- MeSH
- Chemotherapy, Adjuvant * methods statistics & numerical data MeSH
- Survival Analysis MeSH
- Cisplatin therapeutic use MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Interdisciplinary Communication MeSH
- Lung Neoplasms * drug therapy mortality pathology therapy MeSH
- Carcinoma, Non-Small-Cell Lung * drug therapy mortality pathology surgery MeSH
- Pneumonectomy * methods statistics & numerical data MeSH
- Antineoplastic Agents therapeutic use MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Drug Utilization statistics & numerical data MeSH
- Neoplasm Staging MeSH
- Vinorelbine therapeutic use MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Cisplatin MeSH
- Antineoplastic Agents MeSH
- Vinorelbine MeSH
OBJECTIVES: Adjuvant chemotherapy (AC) in non-small cell lung cancer (NSCLC) has become a standard of care in patients with stages IIA, IIB, and IIIA after complete tumor resection. Utilization and outcome of AC in routine practice is described in a few studies, with non-conclusive results. MATERIALS AND METHODS: This retrospective study included consecutive patients with NSCLC who underwent curative-intent surgery. Data of AC uptake in stages IB (tumor of ≥4 cm in diameter), II, and IIIA, and reasons of AC omission were evaluated according to medical records. Mortality risk among patients treated with surgery (only) and different types of AC in routine practice was compared. RESULTS: AC was applied to 79% of patients with stages IB (tumor of ≥4 cm in diameter), II, and IIIA, and was associated with an improved median of overall survival (HR = 0.69; 95% CI = 0.44-1.06). Significantly longer survival was achieved in the sub-group treated with platinum and oral vinorelbine (HR = 0.575, 95% CI = 0.339-0.974), and the longest survival was among patients treated with oral vinorelbine and cisplatin (HR = 0.371, 95% CI = 0.168-0.820). CONCLUSIONS: AC utilization should be based on co-operation between surgeons, pneumo-oncologists, and patients. Rational use of AC offers better survival in routine practice.
b Department of Surgery University Hospital Olomouc Olomouc Czech Republic
c Department of Molecular Pathology Palacky University Olomouc Czech Republic
Department of Respiratory Medicine University Hospital Olomouc Olomouc Czech Republic
References provided by Crossref.org
